X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with Dr. Reddys - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs DR. REDDYS LAB - Comparison Results

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA DR. REDDYS LAB AJANTA PHARMA/
DR. REDDYS LAB
 
P/E (TTM) x 20.0 27.3 73.2% View Chart
P/BV x 8.6 2.8 307.2% View Chart
Dividend Yield % 0.7 1.0 69.0%  

Financials

 AJANTA PHARMA   DR. REDDYS LAB
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-16
DR. REDDYS LAB
Mar-16
AJANTA PHARMA/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs1,7204,383 39.2%   
Low Rs1,1032,750 40.1%   
Sales per share (Unadj.) Rs194.6920.1 21.2%  
Earnings per share (Unadj.) Rs45.2126.1 35.9%  
Cash flow per share (Unadj.) Rs50.3183.0 27.5%  
Dividends per share (Unadj.) Rs8.0020.00 40.0%  
Dividend yield (eoy) %0.60.6 101.1%  
Book value per share (Unadj.) Rs132.0685.8 19.3%  
Shares outstanding (eoy) m88.77170.61 52.0%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x7.33.9 187.1%   
Avg P/E ratio x31.228.3 110.4%  
P/CF ratio (eoy) x28.119.5 144.0%  
Price / Book Value ratio x10.75.2 205.6%  
Dividend payout %17.715.9 111.5%   
Avg Mkt Cap Rs m125,299608,481 20.6%   
No. of employees `000NA21.7 0.0%   
Total wages/salary Rs m2,57031,874 8.1%   
Avg. sales/employee Rs ThNM7,244.4-  
Avg. wages/employee Rs ThNM1,470.9-  
Avg. net profit/employee Rs ThNM992.8-  
INCOME DATA
Net Sales Rs m17,275156,978 11.0%  
Other income Rs m1662,693 6.2%   
Total revenues Rs m17,442159,671 10.9%   
Gross profit Rs m5,80734,587 16.8%  
Depreciation Rs m4519,705 4.6%   
Interest Rs m49824 5.9%   
Profit before tax Rs m5,47426,751 20.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,4605,237 27.9%   
Profit after tax Rs m4,01421,514 18.7%  
Gross profit margin %33.622.0 152.6%  
Effective tax rate %26.719.6 136.2%   
Net profit margin %23.213.7 169.5%  
BALANCE SHEET DATA
Current assets Rs m7,639118,201 6.5%   
Current liabilities Rs m2,71568,368 4.0%   
Net working cap to sales %28.531.7 89.8%  
Current ratio x2.81.7 162.8%  
Inventory Days Days4360 72.1%  
Debtors Days Days7997 81.2%  
Net fixed assets Rs m6,91472,265 9.6%   
Share capital Rs m177853 20.7%   
"Free" reserves Rs m11,442111,548 10.3%   
Net worth Rs m11,721117,009 10.0%   
Long term debt Rs m14910,690 1.4%   
Total assets Rs m14,814200,104 7.4%  
Interest coverage x112.933.5 337.5%   
Debt to equity ratio x00.1 13.9%  
Sales to assets ratio x1.20.8 148.6%   
Return on assets %27.411.2 245.7%  
Return on equity %34.218.4 186.3%  
Return on capital %46.521.6 215.5%  
Exports to sales %55.146.3 119.2%   
Imports to sales %6.09.0 67.1%   
Exports (fob) Rs m9,52772,618 13.1%   
Imports (cif) Rs m1,03814,050 7.4%   
Fx inflow Rs m10,42275,405 13.8%   
Fx outflow Rs m1,67827,115 6.2%   
Net fx Rs m8,74448,290 18.1%   
CASH FLOW
From Operations Rs m3,26440,476 8.1%  
From Investments Rs m-2,093-19,421 10.8%  
From Financial Activity Rs m-1,186-17,009 7.0%  
Net Cashflow Rs m-154,046 -0.4%  

Share Holding

Indian Promoters % 73.8 25.5 289.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.6 5.4 28.7%  
FIIs % 7.6 35.3 21.5%  
ADR/GDR % 0.0 18.5 -  
Free float % 17.0 15.3 111.1%  
Shareholders   20,968 75,885 27.6%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   STRIDES SHASUN LTD  ELDER PHARMA  SUVEN LIFE  DR. DATSONS LABS  WOCKHARDT LTD.  

Compare AJANTA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Recovery of Global Markets, Apex Frozen Food IPO & Cues to Watch Out Today(Pre-Open)

Indian stock markets remained range-bound in lacklustre trade on Tuesday as market participants kept to the sidelines in the absence of clear triggers.

Related Views on News

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Dr Reddy's: Major Business Segments Come Under Pressure (Quarterly Results Update - Detailed)

Sep 12, 2016

Dr Reddy's has announced the results for first quarter of FY17 (1QFY17). The company has reported decline in the sales by 13.9% YoY while net profits declined by 79.8 % YoY.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Aug 22, 2017 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 8-QTR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS